Xencor (XNCR) vs Zymeworks (ZYME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Xencor (XNCR) has outperformed Zymeworks (ZYME) over the past year, gaining 97.6% versus a gain of 60.8%. Over five years, ZYME leads with a +2.3% price change compared with -36.9% for XNCR. Xencor is the larger company by market cap ($1.82 billion vs $1.81 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | XNCR | ZYME |
|---|---|---|
| Share price | $24.50 | $25.26 |
| Market cap | $1.82B | $1.81B |
| 1-day change | +0.99% | -4.79% |
| YTD return | +60.03% | +0.76% |
| 1-year return | +97.58% | +60.79% |
| 5-year return | -36.94% | +2.27% |
| Forward P/E | — | 28.97 |
| EPS (TTM) | $-2.16 | $-2.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $30.61 | $31.34 |
| 52-week low | $10.38 | $16.00 |
| Distance from 52-week high | -19.96% | -19.40% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +28.24% | +63.14% |
| Average volume | 1.31M | 687.87K |
| Shares outstanding | 74.35M | 71.20M |
| Employees | 260 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XNCR has outperformed ZYME by 36.8 percentage points over the past year.
About Xencor
XNCR stock →Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
About Zymeworks
ZYME stock →Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
XNCR vs ZYME FAQ
Which is bigger, Xencor or Zymeworks?
Xencor (XNCR) is larger, with a market capitalization of $1.82B compared with $1.81B for Zymeworks (ZYME).
Which stock has performed better over the past year, XNCR or ZYME?
XNCR returned +97.58% over the past 12 months, compared with +60.79% for ZYME (price return, excluding dividends). Past performance does not predict future results.
Are Xencor and Zymeworks in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.